Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus

ABSTRACT Severe fever with thrombocytopenia syndrome virus (SFTSV) is the causative agent of SFTS, an emerging hemorrhagic fever. This disease has a high case fatality rate and is endemic to China, South Korea, and Japan. Because there are currently no effective therapeutics for SFTS, potent and saf...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hideki Tani, Aiko Fukuma, Shuetsu Fukushi, Satoshi Taniguchi, Tomoki Yoshikawa, Naoko Iwata-Yoshikawa, Yuko Sato, Tadaki Suzuki, Noriyo Nagata, Hideki Hasegawa, Yasuhiro Kawai, Akihiko Uda, Shigeru Morikawa, Masayuki Shimojima, Haruo Watanabe, Masayuki Saijo
Formato: article
Lenguaje:EN
Publicado: American Society for Microbiology 2016
Materias:
Acceso en línea:https://doaj.org/article/a907b03c91a445f0be2fcc816c35eb99
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a907b03c91a445f0be2fcc816c35eb99
record_format dspace
spelling oai:doaj.org-article:a907b03c91a445f0be2fcc816c35eb992021-11-15T15:21:37ZEfficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus10.1128/mSphere.00061-152379-5042https://doaj.org/article/a907b03c91a445f0be2fcc816c35eb992016-02-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mSphere.00061-15https://doaj.org/toc/2379-5042ABSTRACT Severe fever with thrombocytopenia syndrome virus (SFTSV) is the causative agent of SFTS, an emerging hemorrhagic fever. This disease has a high case fatality rate and is endemic to China, South Korea, and Japan. Because there are currently no effective therapeutics for SFTS, potent and safe antivirals are needed for the treatment of SFTS. The inhibitory effect of T-705 (favipiravir) on the replication of SFTSV in Vero cells was evaluated. Mice lacking the type I interferon receptor (IFNAR−/−) were used as an in vivo lethal model for SFTSV infection. T-705, which has been licensed as an anti-influenza drug in Japan, inhibits SFTSV replication both in vitro and in vivo. T-705 inhibited replication of SFTSV in Vero cells by 5 log units, with a 50% inhibitory concentration (IC50) and IC90 of 6.0 µM and 22 µM, respectively. Intraperitoneal or oral administration of T-705 for 5 days to IFNAR−/− mice infected with lethal SFTSV significantly improved survival rates (100% survival) without causing body weight loss and reduced the viral load in the serum. Ribavirin also inhibited SFTSV replication. However, it was less effective than T-705 both in vitro and in vivo. A time-of-drug-addition study revealed that therapeutic T-705 treatment of SFTSV infection in IFNAR−/− mice was effective. These results suggest that T-705 is a promising candidate for the treatment of SFTS. IMPORTANCE Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a recently identified emerging viral infectious disease. Despite the medical importance of this disease, there are currently neither vaccines nor effective therapeutics for SFTS. T-705, which is a pyrazine derivative, has shown broad antiviral activity against various RNA viruses. The present study demonstrated, for the first time to our knowledge, the efficacy of T-705 in treating SFTSV infection in a mouse lethal model. T-705 showed a high efficacy in the treatment of SFTSV infection in the mouse model, even when treatments were initiated after onset of the disease.Hideki TaniAiko FukumaShuetsu FukushiSatoshi TaniguchiTomoki YoshikawaNaoko Iwata-YoshikawaYuko SatoTadaki SuzukiNoriyo NagataHideki HasegawaYasuhiro KawaiAkihiko UdaShigeru MorikawaMasayuki ShimojimaHaruo WatanabeMasayuki SaijoAmerican Society for MicrobiologyarticleSFTSfavipiravirefficacyinfectiontype I interferonT-705MicrobiologyQR1-502ENmSphere, Vol 1, Iss 1 (2016)
institution DOAJ
collection DOAJ
language EN
topic SFTS
favipiravir
efficacy
infection
type I interferon
T-705
Microbiology
QR1-502
spellingShingle SFTS
favipiravir
efficacy
infection
type I interferon
T-705
Microbiology
QR1-502
Hideki Tani
Aiko Fukuma
Shuetsu Fukushi
Satoshi Taniguchi
Tomoki Yoshikawa
Naoko Iwata-Yoshikawa
Yuko Sato
Tadaki Suzuki
Noriyo Nagata
Hideki Hasegawa
Yasuhiro Kawai
Akihiko Uda
Shigeru Morikawa
Masayuki Shimojima
Haruo Watanabe
Masayuki Saijo
Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
description ABSTRACT Severe fever with thrombocytopenia syndrome virus (SFTSV) is the causative agent of SFTS, an emerging hemorrhagic fever. This disease has a high case fatality rate and is endemic to China, South Korea, and Japan. Because there are currently no effective therapeutics for SFTS, potent and safe antivirals are needed for the treatment of SFTS. The inhibitory effect of T-705 (favipiravir) on the replication of SFTSV in Vero cells was evaluated. Mice lacking the type I interferon receptor (IFNAR−/−) were used as an in vivo lethal model for SFTSV infection. T-705, which has been licensed as an anti-influenza drug in Japan, inhibits SFTSV replication both in vitro and in vivo. T-705 inhibited replication of SFTSV in Vero cells by 5 log units, with a 50% inhibitory concentration (IC50) and IC90 of 6.0 µM and 22 µM, respectively. Intraperitoneal or oral administration of T-705 for 5 days to IFNAR−/− mice infected with lethal SFTSV significantly improved survival rates (100% survival) without causing body weight loss and reduced the viral load in the serum. Ribavirin also inhibited SFTSV replication. However, it was less effective than T-705 both in vitro and in vivo. A time-of-drug-addition study revealed that therapeutic T-705 treatment of SFTSV infection in IFNAR−/− mice was effective. These results suggest that T-705 is a promising candidate for the treatment of SFTS. IMPORTANCE Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV), is a recently identified emerging viral infectious disease. Despite the medical importance of this disease, there are currently neither vaccines nor effective therapeutics for SFTS. T-705, which is a pyrazine derivative, has shown broad antiviral activity against various RNA viruses. The present study demonstrated, for the first time to our knowledge, the efficacy of T-705 in treating SFTSV infection in a mouse lethal model. T-705 showed a high efficacy in the treatment of SFTSV infection in the mouse model, even when treatments were initiated after onset of the disease.
format article
author Hideki Tani
Aiko Fukuma
Shuetsu Fukushi
Satoshi Taniguchi
Tomoki Yoshikawa
Naoko Iwata-Yoshikawa
Yuko Sato
Tadaki Suzuki
Noriyo Nagata
Hideki Hasegawa
Yasuhiro Kawai
Akihiko Uda
Shigeru Morikawa
Masayuki Shimojima
Haruo Watanabe
Masayuki Saijo
author_facet Hideki Tani
Aiko Fukuma
Shuetsu Fukushi
Satoshi Taniguchi
Tomoki Yoshikawa
Naoko Iwata-Yoshikawa
Yuko Sato
Tadaki Suzuki
Noriyo Nagata
Hideki Hasegawa
Yasuhiro Kawai
Akihiko Uda
Shigeru Morikawa
Masayuki Shimojima
Haruo Watanabe
Masayuki Saijo
author_sort Hideki Tani
title Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
title_short Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
title_full Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
title_fullStr Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
title_full_unstemmed Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
title_sort efficacy of t-705 (favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus
publisher American Society for Microbiology
publishDate 2016
url https://doaj.org/article/a907b03c91a445f0be2fcc816c35eb99
work_keys_str_mv AT hidekitani efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT aikofukuma efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT shuetsufukushi efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT satoshitaniguchi efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT tomokiyoshikawa efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT naokoiwatayoshikawa efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT yukosato efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT tadakisuzuki efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT noriyonagata efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT hidekihasegawa efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT yasuhirokawai efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT akihikouda efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT shigerumorikawa efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT masayukishimojima efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT haruowatanabe efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
AT masayukisaijo efficacyoft705favipiravirinthetreatmentofinfectionswithlethalseverefeverwiththrombocytopeniasyndromevirus
_version_ 1718428149943894016